|
Synonyms: Tarvacin ch3G4
Compound class:
Antibody
Comment: Bavituximab is the first monoclonal antibody directed against phosphatidylserine, and is being investigated as a antineoplastic agent. Bavituximab belongs to an emerging class of antibodies known as vascular targeting agents (VTAs) which bind selectively to antigens present on tumour vascular cells. Typical VTAs either recruit host effector cells to destroy the tumour or are coupled to agents such as toxins, anticoagulants or pro-apoptotic drugs that occlude or destroy tumour blood vessels [3].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 8734 | bavituximab |
| Synonyms |
| Tarvacin ch3G4 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 149 |
| Other databases | |
| GtoPdb PubChem SID | 249565682 |
| Search PubMed clinical trials | bavituximab |
| Search PubMed titles | bavituximab |
| Search PubMed titles/abstracts | bavituximab |
| Wikipedia | Bavituximab |
